#tecentriq — Public Fediverse posts

https://www.europesays.com/ch/115356/ Roche’s Tecentriq nabs ctDNA-guided bladder cancer nod #FiercePharmaHomepage #Genentech #Natera #Pharma #Roche #Tecentriq

https://www.europesays.com/ch/86919/ Jazz, Roche’s small cell lung cancer combo snags FDA approval #CombinationTherapy #DrugCombinations #FDAApproval #FDAApprovals #FiercePharmaHomepage #JazzPharmaceuticals #marketing #Oncology #Pharma #Roche #SmallCellLungCancer #Tecentriq

https://www.europesays.com/ch/86592/ As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study #BreastCancer #BTKInhibitors #ClinicalData #Earnings #FiercePharmaHomepage #financials #MultipleSclerosis #NonSmallCellLungCancer #PD1/L1 #Pharma #Roche #Tecentriq #TeresaGraham #Vabysmo #WetAMD

https://www.europesays.com/ch/86490/ After delay, Roche’s Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug #FiercePharmaHomepage #HalozymeTherapeutics #Pharma #Roche #SubcutaneousDrugDelivery #Tecentriq

https://www.europesays.com/ch/84852/ FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer #AdjuvantTreatment #atomic #cancer #CancerImmunotherapy #chemotherapy #ColonCancer #DiseaseRecurrence #DNAMismatchRepair #Roche #StageIII #Tecentriq

https://www.europesays.com/ch/81739/ Roche’s Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer #AdjuvantTreatment #CancerImmunotherapy #chemotherapy #ColonCancer #EarningsPerShare #FDA #patients #Roche #Tecentriq #TecentriqHybreza #ZacksInvestmentResearch

https://www.europesays.com/ch/81361/ Roche wins FDA Priority Review for Tecentriq colon use #ATOMICStudy #ColonCancer #dMMR #FDAPriorityReview #MSIH #RHHBY #Roche #Tecentriq

https://www.europesays.com/ch/81254/ FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer #AdjuvantTreatment #atomic #cancer #CancerImmunotherapy #chemotherapy #ColonCancer #DiseaseRecurrence #DNAMismatchRepair #Roche #StageIII #Tecentriq

https://www.europesays.com/ch/69789/ Roche’s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer #BladderCancer #DiseaseRecurrence #EligiblePatients #FDA #Roche #Tecentriq #TreatmentStrategy #ZacksInvestmentResearch

https://www.europesays.com/ch/67577/ Roche’s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer #BladderCancer #DiseaseRecurrence #EligiblePatients #FDA #Roche #Tecentriq #TreatmentStrategy #ZacksInvestmentResearch

https://www.europesays.com/ch/65576/ Roche Unveils Subcutaneous Tecentriq for Lung Cancer Treatment in India, ETPharma #CancerImmunotherapy #PDL1Inhibitor #Roche #SubcutaneousFormulation #Tecentriq

https://www.europesays.com/ch/65474/ Roche brings 7-minute lung cancer shot to India #DCGIApproval #immunotherapy #LungCancerTreatment #NonSmallCellLungCancer #Roche #RochePharmaIndia #SubcutaneousInjection #Tecentriq

https://www.europesays.com/ch/65233/ Roche launches subcutaneous lung cancer immunotherapy, cuts delivery time to 7 min #DeliveryTime #immunotherapy #LungCancer #Roche #subcutaneous #Tecentriq

https://www.europesays.com/ch/65202/ Roche India Launches First Under-the-Skin Lung Cancer Therapy #7MinuteTreatment #atezolizumab #CancerCareIndia #immunotherapy #LungCancer #NSCLC #Oncology #Roche #RochePharmaIndia #SubcutaneousInjection #Tecentriq

https://www.europesays.com/ch/65167/ Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancer #CancerCare #immunotherapy #India #IVInfusion #LungCancer #MedicalOncology #NSCLC #Roche #RochePharma #SubcutaneousInjection #Tecentriq

A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home

A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home

A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home

A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home